Product Overview
[Drug Name]
Generic Name: Nifedipine Sustained-Release Tablets (I)
Trade Name: Yabao Yixin
English Name: Nifedipine Sustained-Release Tablets (I)
Pinyin: Xiaobendiping Huanshi Pian
[Ingredients]
The main ingredient of this product is nifedipine.
[Properties]
This product is a film-coated tablet that appears yellow after removal of the film coating.
[Indications]
Various types of hypertension and angina pectoris
[Dosage and Administration]
Oral administration: 1-2 tablets twice daily. Maximum dose: 4 tablets at a time, 12 tablets daily.
[Adverse Reactions]
1. Liver: Occasionally, jaundice and elevated glutamate oxaloacetate aminotransferase and glutamate pyruvate aminotransferase levels may occur.
2. Circulatory System: Occasionally, chest pain, headache, flushing, dizziness, palpitations, decreased blood pressure, and lower limb edema may occur.
3. Allergies: Occasionally, allergic symptoms such as hives and itching may occur.
4. Digestive System: Occasionally, abdominal pain, nausea, loss of appetite, and constipation may occur.
5. Oral: Gingival hypertrophy may occur.
6. Metabolic Abnormalities: Occasionally, hyperglycemia may occur.
[Contraindications]: Contraindicated in children and pregnant women.
[Precautions]
1. Discontinue use. Calcium antagonists should be gradually reduced in dosage. Do not discontinue medication without a doctor's advice. 2. Use with caution in patients with hypotension. 3. Use with caution in patients with severe aortic valve stenosis or hepatic or renal insufficiency.
[Special Population Use]
Precautions for Children: Contraindicated in children.
Precautions for Pregnant and Lactating Women: Contraindicated in pregnant women.
Precautions for Elderly: This study has not been conducted and no reliable references are available.
[Drug Interactions]
Unknown.
[Pharmacological Action]
Nifedipine is a dihydropyridine calcium antagonist that selectively inhibits transmembrane calcium transport into myocardial and smooth muscle cells and inhibits calcium release from intracellular stores without altering plasma calcium concentrations. Pharmacology: Nifedipine can dilate coronary arteries in both normal and ischemic areas, antagonizing spontaneous and ergonovine-induced coronary artery spasm, increasing myocardial oxygen delivery, and relieving and preventing coronary artery spasm. It also inhibits myocardial contraction, reduces myocardial metabolism, and decreases myocardial oxygen consumption. On the other hand, it can dilate peripheral resistance vessels, reducing peripheral resistance, lowering systolic and diastolic blood pressure, and alleviating cardiac afterload. This product can delay sinoatrial node function and atrioventricular conduction in isolated hearts; electrophysiological studies in whole animals and humans have not shown that this product delays atrioventricular conduction, prolongs sinoatrial node recovery time, or slows sinoatrial node rate. Toxicology (carcinogenicity, mutagenicity, and reproductive toxicity): No carcinogenic effects. No mutagenicity. High doses can reduce female rat fertility; can cause teratogenicity; and can induce abortion (increased fetal drug absorption, increased fetal mortality, and decreased neonatal survival). Administration of 2/3 to 2 times the maximum human dose to pregnant monkeys can result in small placentas and incomplete villous development; administration of 3 times the maximum human dose to rats can cause prolonged gestation.
[Storage] Store in a dark, airtight container. [Specification] 10mg x 30 tablets
[Packaging] Box
[Validity Period] 12 months
[Approval Number] National Medicine Standard H14020439
[Manufacturer] Company Name: Yabao Pharmaceutical Group Co., Ltd.
